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PD-1-centered therapies rely on CD28 activation to promote anti-tumor
immunity
Drugs targeting PD-1 and CTLA-4 have been the trailblazers of cancer immunotherapy and
have distinct response rates and side effect profiles. However, recent work published in
Science (1, 2) suggests that these two molecules may have more in common than we
thought. The new studies reveal that PD-1 primarily works by inhibiting signaling through
CD28, an important costimulatory receptor that promotes T cell activation. This is intriguing
given that CTLA-4 also regulates the CD28 pathway.
To elucidate the molecular interactions mediated by PD-1, Hui et al (1) employed an elegant
cell free system. They displayed the cytoplasmic tail of PD-1 on liposomes and used a
Fluorescence Resonance Energy Transfer (FRET)-based assay to show Lck is the main
kinase that phosphorylates it. Next, they explored which SH2-domain-containing proteins
bind to phosphorylated PD-1. Shp2 (but not Shp1) was efficiently recruited to
phosphorylated PD-1, with both tyrosines in the PD-1 cytoplasmic tail contributing to this
recruitment. Armed with the identity of the main PD-1 effector molecule, the authors then
addressed a key outstanding question in the field - which mediators of T cell activation does
PD-1 actually inhibit? They modified their liposome system to incorporate an array of the
usual suspects including TCR, CD28, CD3ζ, and ZAP70 and assessed how efficiently PD-1-
Shp2 dephosphorylated them. Strikingly, PD-1 extinguished CD28 phosphorylation with the
highest efficiency. While TCR signaling components were also dephosphorylated, this
required many more PD-1 molecules to be present. In a direct comparison between CD28
and CD3ζ, it was found that both were dephosphorylated by PD-1-Shp2, but the re-
phosphorylation of CD3ζ by Lck was more efficient. The net consequence was that PD-1-
Shp2 could rapidly decrease the number of phosphorylated CD28 molecules while barely
affecting CD3ζ molecules. Consistent with regulation of CD28, TIRF microscopy revealed
tight co-clustering of PD-1 and CD28 in T cells as they interacted with their ligands on a
supported lipid bilayer. These data build on the previous identification of PD-1-Shp2
inhibitory microclusters (3) but reveal a preference for CD28 as the target for inhibition.
Corresponding author: Prof Lucy S.K. Walker, Institute of Immunity & Transplantation, University College London Division of
Infection & Immunity, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. lucy.walker@ucl.ac.uk.*This manuscript has been accepted for publication in Science Immunology. This version has not undergone final editing. Please refer
to the complete version of record at http://immunology.sciencemag.org. The manuscript may not be reproduced or used in any manner
that does not fall within the fair use provisions of the Copyright Act without the prior, written permission of AAAS.
Europe PMC Funders Group
Author Manuscript
Sci Immunol. Author manuscript.
Published in final edited form as:
Sci Immunol. ; 2: . doi:10.1126/sciimmunol.aan3864.
 Europe PMC Funders Author Manuscripts
 Europe PMC Funders Author Manuscripts
So what are the physiological implications of these findings? Dovetailing with this article, a
study from Kamphorst et al. (2) probed the interplay between the PD-1 and CD28 systems in
vivo. Following chronic lymphocytic choriomeningitis virus (LCMV) infection in mice, they
show that anti-PD-L1 mediated rescue of T cell exhaustion depends on CD28 costimulation.
By blocking the CD28 ligands (B7.1, B7.2), or using CD28-deficient virus-specific T cells,
the authors could virtually negate the actions of anti-PD-L1 antibodies. Might the absence of
costimulation have interfered with the capacity of the T cells to become exhausted in the
first place? To circumvent this possibility, the authors used an inducible model that allowed
CD28 to be ablated from a fraction of T cells once exhaustion had been established. Again,
T cells that had lost CD28 were refractory to anti-PD-L1 treatment. One link between the
PD-1 and CD28 pathways is that PD-L1 can bind B7.1, however similar results were
obtained using antibodies directed against PD-1, arguing against a role for this partnership
here. CD28 costimulation was also found to be required for the anti-tumor effects of anti-
PD-L1 in a colon carcinoma model. After anti-PD-L1 treatment, only 1 out of 9 mice
showed tumor progression, but if B7 ligands were also blocked tumors progressed in 8 out
of 10 mice. Thus, for PD-1 pathway inhibition to unleash the immune response to tumor, a
functional B7-CD28 costimulatory axis is required.
Turning from mice to humans, the authors studied blood samples from lung cancer patients
receiving immunotherapy. After PD-1 blockade, an increase in proliferating CD8 T cells
was seen in ~50% of patients and crucially nearly all of these cells expressed CD28. While
CD28 is normally found on most T cells, it can be downregulated by chronic stimulation,
including in the tumor microenvironment (2). Whether the ratio of CD28+/CD28- T cells
changes following immunotherapy, and how this relates to response rates, are tantalizing
future questions.
The archetypal regulator of the CD28 pathway is the inhibitory protein CTLA-4. CTLA-4
shares ligands with CD28 but binds them with higher affinity: it therefore serves as a ligand
competitor and can also downregulate B7 expression on antigen presenting cells (4). Since
CTLA4 governs access to the B7 ligands, CTLA-4-mediated immune regulation is strictly
focused on the CD28 pathway. This is elegantly demonstrated by the finding that immune
hyperactivation in CTLA-4-deficient mice depends on signaling motifs in the CD28
cytoplasmic tail (5). Thus, CTLA-4 regulates the ability of CD28 to bind its ligands while
PD-1 regulates CD28 signaling (Figure 1). An implication of this work is that combinations
of drugs targeting CTLA-4 and PD-1 may work synergistically since blocking CTLA-4
increases availability of CD28 ligands and blocking PD-1 increases T cell sensitivity to
CD28 ligation.
If PD-1 and CTLA-4 both regulate the CD28 pathway, does that make them functionally
equivalent? There are several reasons why this is not the case. Arguably the most important
distinction is the mode of operation of the two molecules. Extensive evidence indicates that
CTLA-4 functions primarily in a cell-extrinsic manner - i.e. that CTLA-4 expressed on one
T cell regulates the activation of another T cell, most likely by competing for and
downregulating B7 ligands (reviewed in (4)). PD-1 on the other hand acts directly on the T
cells that express it. This simple distinction means that even if both regulatory pathways
converge on CD28, the circumstances in which regulation is elicited are likely to be very
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different. CTLA-4 is highly expressed in regulatory T cells (Treg) where it can be used to
control the priming of naive T cells. It is also upregulated on activated T cells where, similar
to the situation in Treg, it can operate in a cell-extrinsic manner to regulate the CD28-
dependent activation of other T cells. Conversely, PD-1 is not thought to regulate T cell
priming since it is absent from resting T cells. Although expressed on Treg, PD-1 is
dispensable for their suppressive function (6). Accordingly, CTLA-4-deficient mice
resemble Treg-deficient mice whereas PD-1-deficient mice do not. Instead, PD-1 directly
regulates antigen-experienced T cells and is a characteristic marker of the exhausted CD8 T
cells that arise during chronic stimulation. The regulation of T cell exhaustion is complex,
however recent studies suggest the transcription factor TCF1 can define less exhausted and
more exhausted populations (TCFhigh and TCFlow respectively) (7) with exciting data
indicating it is the former population that responds to PD-1 blockade (8). New findings from
the autoimmunity field provide additional support for the notion of heterogeneity within
exhausted populations: anti-CD3 immunotherapy was shown to induce partial exhaustion in
CD8 cells that could be further deepened upon TIGIT engagement (9). Thus, definitions of
the populations influenced by PD-1 engagement are still emerging and an increased
understanding of exhausted states will doubtless illuminate this issue further. Finally,
although PD-1 preferentially regulates CD28, TCR signaling components do not completely
escape its reach (1). Thus, while CTLA-4-based regulation is strictly CD28-dependent, PD-1
can also regulate other pathways, particularly in cell types that do not express CD28 such as
B cells (10).
Collectively the new studies underscore the pivotal role of the CD28 pathway in T cell
immunity and highlight the diverse mechanisms that have evolved to regulate it: CTLA-4
controlling access to B7 ligands, PD-1 controlling CD28 signaling and CD28
downregulation vetoing use of this pathway altogether. They also illustrate how mechanistic
understanding of inhibitory receptor function could be used to guide selection of
combination therapies. One could envisage teaming a cell-extrinsic regulator with a cell-
intrinsic one, or a ligand-competitor with a signaling inhibitor. Moreover, combining agents
that require CD28 signaling (such as PD-L1 antibodies) with drugs that promote CD28 re-
expression could represent an attractive strategy to improve responses to immunotherapy.
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Figure 1. Extrinsic and intrinsic regulation of CD28.
CTLA-4 regulates CD28 ligand-binding while PD-1 inhibits CD28 signaling. CD28
costimulation is required for anti-PD-L1 antibodies to enhance immunity.
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